Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 49
Inquire Before Buying

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2018, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Overview
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Companies Involved in Therapeutics Development
Array BioPharma Inc
AstraZeneca Plc
Pfizer Inc
SpringWorks Therapeutics LLC
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Drug Profiles
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-0325901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurofibromatoses Type I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Dormant Projects
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2012: Study Identifies Targeted Molecular Therapy For Untreatable NF1 Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen's Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Array BioPharma Inc, H1 2018
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by AstraZeneca Plc, H1 2018
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Pfizer Inc, H1 2018
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by SpringWorks Therapeutics LLC, H1 2018
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Dormant Projects, H1 2018

List of Figures
Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen's Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Adult Cooling Sheet Market Insights, Forecast to 2025
    Published: 18-Dec-2018        Price: US 3900 Onwards        Pages: 111
    In 2017, the global Adult Cooling Sheet market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Adult Cooling Sheet market based on company, product type, application and key regions. This report studies the global market size of Adult Cooling Sheet in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focu......
  • Global Baby Cooling Sheet Market Insights, Forecast to 2025
    Published: 18-Dec-2018        Price: US 3900 Onwards        Pages: 113
    In 2017, the global Baby Cooling Sheet market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Baby Cooling Sheet market based on company, product type, application and key regions. This report studies the global market size of Baby Cooling Sheet in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses......
  • Global Microneedle Drug Delivery Systems Market Professional Survey Report 2018
    Published: 18-Dec-2018        Price: US 3500 Onwards        Pages: 147
    This report studies the global Microneedle Drug Delivery Systems market status and forecast, categorizes the global Microneedle Drug Delivery Systems market size by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, China, Japan, Southeast Asia, India and ROW. Intradermal drug delivery is increasingly recognized as a potential solution to many of the challenges faced by new and existing medicines. Intradermal dosing......
  • Global Cooling Sheet Market Insights, Forecast to 2025
    Published: 18-Dec-2018        Price: US 3900 Onwards        Pages: 116
    In 2017, the global Cooling Sheet market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Cooling Sheet market based on company, product type, application and key regions. This report studies the global market size of Cooling Sheet in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consump......
  • Global Polygeline Injection Market Insights, Forecast to 2025
    Published: 18-Dec-2018        Price: US 3900 Onwards        Pages: 119
    In 2017, the global Polygeline Injection market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Polygeline Injection market based on company, product type, application and key regions. This report studies the global market size of Polygeline Injection in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, f......
  • Global Gelatin Polypeptide Plasma Expander Market Insights, Forecast to 2025
    Published: 18-Dec-2018        Price: US 3900 Onwards        Pages: 119
    In 2017, the global Gelatin Polypeptide Plasma Expander market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Gelatin Polypeptide Plasma Expander market based on company, product type, application and key regions. This report studies the global market size of Gelatin Polypeptide Plasma Expander in key regions like North America, Europe, Asia Pacific, Centra......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Consumer Healthcare Market 2018, Forecast to 2023
    Published: 18-Dec-2018        Price: US 4880 Onwards        Pages: 145
    Consumer healthcare products include trusted brands of multivitamins and iron supplements, in addition to products for allergies, personal hygiene, sleep support, alertness and cold and flu. Scope of the Report: This report focuses on the Consumer Healthcare in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Consumer he......
  • Global Erwinia L-Asparaginase Market Insights, Forecast to 2025
    Published: 18-Dec-2018        Price: US 3900 Onwards        Pages: 115
    Erwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. The global Erwinia L-Asparaginase market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025. The objectives of this study are to define, segment,......
  • Global Erwinia L-Asparaginase Drugs Market Insights, Forecast to 2025
    Published: 18-Dec-2018        Price: US 3900 Onwards        Pages: 116
    Erwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. The global Erwinia L-Asparaginase Drugs market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025. The objectives of this study are to define, se......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs